Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its price objective lifted by Ascendiant Capital Markets from $7.00 to $7.25 in a research report released on Monday,Benzinga reports.

US biotech Atossa Therapeutics (Nasdaq: ATOS) has entered into a research collaboration with China-backed Nona Biosciences, ...

Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Just because a business does not make any ...

Today, several major companies are expected to report earnings: Canadian Solar (CSIQ), Cormedix (CRMD), GameStop (GME), McCormick & Company (MKC), CarParts.com Inc (PRTS), Atossa Therapeutics ...